The Office for Human Research Studies (OHRS) functions as the central office for managing the ethical and scientific review and approval of all cancer-related clinical research protocols conducted by Dana-Farber/Harvard Cancer Center (DF/HCC), with specific responsibilities for supporting the Institutional Review Board and the Protocol Review and Monitoring System.
We are currently seeking a director of OHRS who is highly experienced, strategic, and a well-respected leader who has in-depth knowledge of the numerous issues impacting the review, approval, and oversight of clinical and non-clinical research involving human subjects.
The director of OHRS provides leadership to staff and works in close collaboration with other offices in the management, integration, and improvement of the key processes that support clinical oncology research. The director of OHRS works closely with senior clinical trials officials (clinical trials office, IRB office) and faculty of all of the institutions that participate in the DF/HCC consortium to ensure efficient, responsive and collaborative operations.
Specifically, the director of OHRS is responsible for the leadership and effective management of the office in ensuring administrative and regulatory management and implementation and operation of:
The director is also involved in:
The director is part of both Dana-Farber Cancer Institute (DFCI) and DF/HCC administration. As such the director is expected to work collaboratively with other senior managers within these organizational structures, as well as faculty leaders, departments, individual faculty and staff, and those in member institutions and relevant other organizations.
About Dana-Farber/Harvard Cancer Center (DF/HCC)
Located in Boston and the surrounding communities, Dana-Farber Cancer Institute (DFCI) brings together world renowned clinicians, innovative researchers and dedicated professionals, allies in the common mission of conquering cancer, HIV/AIDS, and related diseases. Combining extremely talented people with the best technologies in a genuinely positive environment, we provide compassionate and comprehensive care to patients of all ages; we conduct research that advances treatment; we educate tomorrow's physician/researchers; we reach out to underserved members of our community; and we work with amazing partners, including other Harvard Medical School-affiliated hospitals.
Dana-Farber Cancer Institute is an equal opportunity employer and affirms the right of every qualified applicant to receive consideration for employment without regard to race, color, religion, sex, gender identity or expression, national origin, sexual orientation, genetic information, disability, age, ancestry, military service, protected veteran status, or other groups as protected by law.
Founded in 1998, the DF/HCC unites the major clinical, population, and basic cancer research efforts of the Dana-Farber Cancer Institute, the Harvard Medical School and Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, the Brigham and Women's Hospital, Boston Children's Hospital, and Massachusetts General Hospital.
DF/HCC is the largest of the Comprehensive Cancer Centers formally designated by the NCI. The DF/HCC links more than 1,100 cancer scientists into an organizational structure designed to foster the interaction and collaboration that will lead to new, more effective approaches cancer prevention, diagnosis, and treatment. Research in the center is carried out in 17 disease-and-discipline based programs that cross both institutional and scientific boundaries. The center also provides infrastructure for more than 16 core facilities that provide shared resources to center members, facilitating scientific progress. Together, these programs and core facilities are fundamental to the multimodality approach to clinical and non-clinical, research and care. The DF/HCC supports the infrastructure for this unified expanded system of cancer research clinical trials.
There are more than 400 new trials reviewed each year and a total of 2,000 open protocols that require continuing IRB review and Scientific Review Committee review. The DFCI IRB is the IRB of record for all cancer relevant trials across all seven DF/HCC consortium members.
Institutional Review Board Review: The OHRS is responsible for implementing the mandate of the Federal Regulations for the Protection of Human Subjects in Research by forming and maintaining an adequate and appropriate number of Institutional Review Boards to ensure efficient review of ethical and safety standards for research involving human subjects. At this time, OHRS manages 7 institution review boards with members from all five of the DF/HCC institutions.
Protocol Review and Monitoring System: Under the CCSG guidelines, the DF/HCC is required to maintain a protocol review and monitoring system. This system ensures appropriate and adequate review of scientific merit, prioritization and annual progress monitoring of all cancer clinical research protocols conducted by the five clinical institutions that comprise the DF/HCC. OHRS is responsible for meeting the needs of scientific review of research by forming and maintaining committees; providing guidance and training to members; and providing oversight and guidance of issues arising within this review process. OHRS manages 4 scientific review committees.
HIPAA: The Health Insurance Portability and Accountability Act is a separate regulatory scheme that requires a system to ensure the protection of protected health information for individuals who participate in research. OHRS is responsible for ensuring compliance with the requirements of HIPAA; communication and coordination with the other DF/HCC institutions as appropriate; as well as direct operationalization of HIPAA in the maintenance of a privacy board.